查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1518475

呼吸道合胞病毒治疗市场 - 依药物类型（帕利珠单抗、利巴韦林、莫他珠单抗）、给药途径（口服、注射、鼻内）、病患类型（成人、儿童）、配销通路与预测，2024 - 2032 年

Respiratory Syncytial Virus Therapeutics Market - By Drugs Type (Palivizumab, Ribavirin, Motavizumab), Route of administration (Oral, Injectable, Intranasal), Patient Type (Adult, Pediatric), Distribution Channel & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在呼吸道感染盛行率不断上升的推动下，呼吸道合胞病毒治疗市场规模在 2024 年至 2032 年期间将以 12.8% 的复合年增长率成长。根据 firsnet.org 报告，慢性阻塞性肺病影响全球近 2 亿人，约占全球人口的 4%，每年导致约 320 万人死亡。 RSV 感染发生率不断上升，加上季节性爆发，推动了对有效治疗和预防措施的需求。我们正在探索 RSV 病毒学、免疫学和抗病毒药物发现的持续努力，包括单株抗体、抗病毒药物和疫苗，旨在提高疗效和患者预后。此外，专注于加强 RSV 感染的早期检测和管理以减轻医疗负担，这将促进 RSV 疗法的普及。

呼吸道合胞病毒治疗产业根据药物类型、给药途径、患者类型、配销通路和地区进行分类。

利巴韦林细分市场将在 2032 年快速成长。它在控制 RSV 感染方面的有效性，特别是在高风险患者群体中，巩固了其作为基石疗法的地位。正在进行的临床试验和研究计划继续探索利巴韦林的功效和安全性，强调其在 RSV 治疗中的重要性。

由于婴幼儿容易受到严重 RSV 感染，儿科细分市场将在 2032 年之前为市场成长创造利润丰厚的机会。医疗保健提供者强调儿科患者的早期诊断和治疗，以预防呼吸窘迫和住院等併发症。儿科专用製剂和疫苗的开发仍然是製药公司的重点领域，旨在解决这一弱势患者群体未满足的医疗需求。

到2032年，欧洲呼吸道合胞病毒治疗产业将出现良好成长，其特征是医疗基础设施健全和医疗支出高。该地区的人口老化和慢性呼吸道疾病的日益流行增加了对有效 RSV 治疗的需求。此外，支持性的政府措施和有利的监管政策透过促进新疗法的及时批准、商业化和可及性来促进市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 慢性呼吸道疾病盛行率不断上升
      • 医疗保健支出增加
      • 药物发现的技术进步
    • 产业陷阱与挑战
      • 监管障碍和审批挑战
      • 发展中国家的医疗基础设施有限
  • 成长潜力分析
  • 监管环境
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

  • 主要趋势
  • 帕利珠单抗
  • 利巴韦林
  • 莫维珠单抗
  • 其他药物类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 口服
  • 可注射
  • 鼻内
  • 其他给药途径

第 7 章：市场估计与预测：按病患类型，2021 - 2032 年

  • 主要趋势
  • 成人
  • 儿科

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局和药局
  • 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Gilead Sciences
  • GSK plc
  • Johnson & Johnson
  • Medivir AB
  • Merck & Co., Inc
  • Pfizer Inc.
  • Sanofi
简介目录
Product Code: 9184

The Respiratory Syncytial Virus Therapeutics Market size will grow at 12.8% CAGR during 2024-2032, driven by the increasing prevalence of respiratory infections. According to firsnet.org, COPD affects nearly 200 million people worldwide, representing approximately 4% of the global population, and results in approximately 3.2 million deaths annually. The rising incidence of RSV infections, coupled with seasonal outbreaks, drives the demand for effective therapeutics and preventive measures. Continuous efforts in RSV virology, immunology, and antiviral drug discovery are being explored, including monoclonal antibodies, antiviral agents, and vaccines, aimed at improving efficacy and patient outcomes. Additionally, the focus on enhancing early detection and management of RSV infections in order to reduce healthcare burden will bolster the popularity of RSV therapeutics.

The respiratory syncytial virus therapeutics industry is classified based on drug type, route of administration, patient type, distribution channel and region.

The ribavirin segment will grow rapidly through 2032. Known for its broad-spectrum antiviral activity, Ribavirin is commonly administered via inhalation or intravenous infusion to reduce viral replication and alleviate symptoms associated with RSV. Its effectiveness in managing RSV infections, especially in high-risk patient populations, has solidified its position as a cornerstone therapy. Ongoing clinical trials and research initiatives continue to explore Ribavirin's efficacy and safety profile, underscoring its significance in RSV therapeutics.

The pediatric segment will create lucrative opportunities for market growth through 2032, due to the vulnerability of infants and young children to severe RSV infections. Healthcare providers emphasize early diagnosis and treatment in pediatric patients to prevent complications such as respiratory distress and hospitalization. The development of pediatric-specific formulations and vaccines remains a key focus area for pharmaceutical companies aiming to address unmet medical needs in this vulnerable patient group.

Europe respiratory syncytial virus therapeutics industry will witness decent growth through 2032, characterized by robust healthcare infrastructure and high medical expenditure. The region's aging population and increasing prevalence of chronic respiratory diseases contribute to the demand for effective RSV treatments. Additionally, supportive government initiatives and favorable regulatory policies promote market growth by facilitating timely approvals and commercialization & accessibility of new therapeutics.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic respiratory conditions
      • 3.2.1.2 Rising healthcare expenditure
      • 3.2.1.3 Technological advancements in drug discovery
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Regulatory hurdles and approval challenges
      • 3.2.2.2 Limited healthcare infrastructure in developing countries
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Palivizumab
  • 5.3 Ribavirin
  • 5.4 Motavizumab
  • 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Injectable
  • 6.4 Intranasal
  • 6.5 Other route of administrations

Chapter 7 Market Estimates and Forecast, By Patient Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adult
  • 7.3 Pediatrics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies & drug stores
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 AstraZeneca PLC
  • 10.3 Bausch Health Companies Inc.
  • 10.4 Gilead Sciences
  • 10.5 GSK plc
  • 10.6 Johnson & Johnson
  • 10.7 Medivir AB
  • 10.8 Merck & Co., Inc
  • 10.9 Pfizer Inc.
  • 10.10 Sanofi